Neumora Therapeutics NMRA
NASDAQ NMRA
$1.31 -0.04 (-2.96%)
At close: Sep 4, 2026 · 4:00 PM EDT

Neumora Therapeutics (NMRA) Debt Ratio (2025 - 2026)

Neumora Therapeutics (NMRA) posted quarterly Debt Ratio of 0.34 for Q1 2026, up 20.58% quarter-over-quarter from 0.29 in Q4 2025.

Analysis

Neumora Therapeutics (NMRA) Debt Ratio (2025 - 2026) Analysis & Trends

Neumora Therapeutics' Debt Ratio history runs 2 years deep, the most recent figure standing at 0.34 for Q1 2026.

  • In Q1 2026, Debt Ratio changed N/A year-over-year to 0.34; the TTM figure through Mar 2026 stood at 0.34 (changed N/A YoY), while the FY2025 annual figure was 0.29, changed N/A from the prior year.
  • Debt Ratio for Q1 2026 stood at 0.34, up from 0.29 in the prior quarter.
  • The five-year high for Debt Ratio was 0.34 in Q1 2026, with the low at 0.09 in Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 0.05
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 0.05
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 0.12
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - 0.47
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 0.26
10 Neumora Therapeutics 243.49 Mn 243.49 Mn - 0.42
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 0.42
Mar 31, 2026 0.34
Dec 31, 2025 0.29
Sep 30, 2025 0.11
Jun 30, 2025 0.09